Urolithin / PD-1 Cancer Research Results

Uro, Urolithin: Click to Expand ⟱

Features:

Urolithins are gut microbiota–derived dibenzopyran-6-one metabolites formed from ellagitannins → ellagic acid. They are the bioactive, systemically relevant forms responsible for most of the anticancer, mitochondrial, and signaling effects attributed to pomegranate and berry consumption.
Ellagic acid itself is largely confined to the gut lumen; urolithins are what reach circulation and tissues.

Urolithin A (UA), Most studied; mitophagy, anticancer, anti-inflammatory

Humans fall into urolithin metabotypes:
Metabotype	Description	            Approx. Population
A	        Produces UA (best profile)	~40%
B	        Produces UB ± UA	       ~25–30%
0	        Non-producer	                ~30%

ROS Modulation (Context-Dependent)
Cancer cells:
-Mild ROS ↑ or redox stress → apoptosis, growth arrest
Normal cells:
-ROS ↓, improved mitochondrial efficiency

This duality is why urolithins are less chemo-antagonistic than classic antioxidants.

Anticancer Signaling
↓ PI3K/AKT/mTOR
↓ Wnt/β-catenin
↓ NF-κB, STAT3
Cell-cycle arrest (G1/S)

Unlike sulforaphane or NAC, urolithins:
-Do not strongly upregulate NRF2 in cancer cells
-May normalize NRF2 signaling in normal cells

Direct Urolithin A Supplements: Bypass microbiome dependency

Urolithin A–type activity — Cancer vs Normal Cell Effects

Rank	Pathway / Axis	Cancer Cells	Normal Cells	Label	Primary Interpretation	Notes
1	Mitophagy / mitochondrial quality control (PINK1–Parkin axis)	↑ mitophagy → loss of mitochondrial reserve	↑ mitophagy → improved mitochondrial fitness	Driver	Mitochondrial pruning and quality enforcement	Urolithins selectively stress cancer cells by removing dysfunctional mitochondria while rejuvenating normal-cell mitochondrial pools
2	Mitochondrial metabolism / bioenergetics	↓ metabolic flexibility; ↓ ATP resilience	↑ oxidative efficiency	Driver	Energy stress vs optimization	Cancer cells are less able to compensate for enforced mitochondrial turnover
3	Reactive oxygen species (ROS)	↑ ROS (secondary to mitochondrial stress)	↓ ROS	Secondary	Metabolism-linked redox shift	ROS changes arise from altered mitochondrial populations, not direct redox cycling
4	AMPK / mTOR nutrient-sensing axis	↑ AMPK; ↓ mTOR signaling	↑ AMPK (adaptive)	Secondary	Catabolic pressure and growth restraint	Energy-sensing pathways reinforce growth suppression in metabolically stressed tumor cells
5	Cell cycle regulation	↓ proliferation / ↑ arrest	↔ spared	Phenotypic	Cytostatic growth limitation	Growth inhibition reflects bioenergetic insufficiency rather than direct CDK inhibition
6	Inflammatory signaling (NF-κB / cytokines)	↓ pro-tumor inflammation	↓ inflammatory tone	Secondary	Anti-inflammatory modulation	Reduced inflammation contributes to chemopreventive and microenvironmental effects
7	NRF2 antioxidant response	↑ NRF2 (adaptive, secondary)	↑ NRF2 (protective)	Adaptive	Redox homeostasis reinforcement	NRF2 activation reflects improved mitochondrial quality and reduced oxidative burden rather than a cytotoxic mechanism
8	Apoptosis sensitivity	↑ sensitivity to apoptosis (stress-context dependent)	↓ apoptosis	Phenotypic	Threshold-dependent cell death	Apoptosis occurs when mitochondrial and energetic stress exceed adaptive capacity

PD-1, Programmed Death-1: Click to Expand ⟱

Source:

Type: protein

PD-1 (Programmed Death-1) is a protein that plays a crucial role in the immune system's ability to fight cancer. It is a checkpoint protein that helps regulate the immune response by preventing the immune system from attacking healthy cells.
PD-1 is often exploited by cancer cells to evade the immune system. Cancer cells can produce proteins that bind to PD-1, inhibiting the immune response and allowing the cancer cells to grow and proliferate unchecked.

However, researchers have discovered that blocking the PD-1 pathway can help restore the immune system's ability to fight cancer. This has led to the development of PD-1 inhibitors, a class of cancer therapies that target the PD-1 protein.

PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype.
PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers).

Scientific Papers found: Click to Expand⟱

4836-

Uro,

Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation

in-vitro,

Var,

FOXO1↑, TumCG↓, PD-1↓, TIM-3↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Proliferation, Differentiation & Cell State ⓘ

FOXO1↑, 1, TumCG↓, 1,

Immune & Inflammatory Signaling ⓘ

PD-1↓, 1,

Cellular Microenvironment ⓘ

TIM-3↓, 1,
Total Targets: 4

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: PD-1, Programmed Death-1

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells